Skip to main
ROIV
ROIV logo

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd has demonstrated a positive outlook primarily due to the successful Phase 3 results of its drug candidate brepocitinib, which shows significant efficacy across skin and muscle manifestations in dermatomyositis, enhancing investor confidence and sentiment. The company's pipeline includes promising candidates like IMVT-1402 for Graves' disease, which is strategically positioned against growing competition, and batoclimab, notable for being the first clinical candidate exhibiting disease-modifying potential in this patient population. The recent increase in revenue estimates for IMVT-1402 further underscores Roivant's strengthening financial projections, emphasizing the potential for future growth within a competitive biopharmaceutical landscape.

Bears say

The financial outlook for Roivant Sciences Ltd is negatively impacted by the failure of several key drug candidates in clinical trials, including brepocitinib and other assets from the IMVT portfolio, raising concerns regarding the company's pipeline viability. Additionally, there are warnings about potential off-target effects from certain mechanisms, which could complicate future developments and regulatory approvals. Finally, the ongoing challenges in achieving clinically significant results in treating conditions such as dermatomyositis and non-infectious uveitis further highlight the risks associated with Roivant’s current and future product offerings.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.